translate English to French: “We are extremely excited about the potential for AEG33773 to treat painful diabetic neuropathy and to expand to other pain and neuropathy indications, based on our extensive preclinical experience with this family of compounds in multiple models of pain and neuropathy," commented Dr. Jon Durkin, Vice-President Research and Preclinical Development at Aegera.
AEG33773 qui a abouti en moins de 12 mois à l’obtention d’une homologation réglementaire auprès de Santé Canada et au traitement d’un premier patient.